[go: up one dir, main page]

EA201490631A1 - Способы культивирования клеток млекопитающих для получения белка - Google Patents

Способы культивирования клеток млекопитающих для получения белка

Info

Publication number
EA201490631A1
EA201490631A1 EA201490631A EA201490631A EA201490631A1 EA 201490631 A1 EA201490631 A1 EA 201490631A1 EA 201490631 A EA201490631 A EA 201490631A EA 201490631 A EA201490631 A EA 201490631A EA 201490631 A1 EA201490631 A1 EA 201490631A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
mammalian cells
protein
cultivation
protein product
Prior art date
Application number
EA201490631A
Other languages
English (en)
Other versions
EA028491B1 (ru
Inventor
Ин Цзин
Чжэнцзянь Ли
Юэмин Цянь
Original Assignee
Бристол-Майерс Сквибб Кампани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43823459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Майерс Сквибб Кампани filed Critical Бристол-Майерс Сквибб Кампани
Publication of EA201490631A1 publication Critical patent/EA201490631A1/ru
Publication of EA028491B1 publication Critical patent/EA028491B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение раскрывает методы и способы для получения белков, в частности гликопротеинов, с помощью культивирования клеток животных или клеток млекопитающих, предпочтительно, но не ограничиваясь ими, подпитываемых культур клеток. В одном аспекте способы включают добавление глюкокортикоидного соединения в процессе периода культивирования. Добавление глюкокортикоидного соединения поддерживает высокую жизнеспособность культивируемых клеток и может приносить повышенный конечный титр продукта белка и высококачественный продукт белка, что определяют, например, содержанием сиаловой кислоты получаемого белка.
EA201490631A 2009-10-06 2010-10-06 СПОСОБ КУЛЬТИВИРОВАНИЯ КЛЕТОК ДЛЯ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig EA028491B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27834309P 2009-10-06 2009-10-06
US12/897,857 US9540426B2 (en) 2009-10-06 2010-10-05 Mammalian cell culture processes for protein production

Publications (2)

Publication Number Publication Date
EA201490631A1 true EA201490631A1 (ru) 2016-05-31
EA028491B1 EA028491B1 (ru) 2017-11-30

Family

ID=43823459

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201490631A EA028491B1 (ru) 2009-10-06 2010-10-06 СПОСОБ КУЛЬТИВИРОВАНИЯ КЛЕТОК ДЛЯ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig
EA201270469A EA025604B1 (ru) 2009-10-06 2010-10-06 СПОСОБ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201270469A EA025604B1 (ru) 2009-10-06 2010-10-06 СПОСОБ ПОЛУЧЕНИЯ ГЛИКОЗИЛИРОВАННОЙ РЕКОМБИНАНТНОЙ МОЛЕКУЛЫ CTLA4Ig

Country Status (26)

Country Link
US (3) US9540426B2 (ru)
EP (1) EP2486048B2 (ru)
JP (1) JP2013506436A (ru)
KR (1) KR20120100973A (ru)
CN (1) CN102753572A (ru)
AR (1) AR078544A1 (ru)
AU (1) AU2010303590B2 (ru)
BR (1) BR112012007854A2 (ru)
CA (1) CA2777050C (ru)
CO (1) CO6531436A2 (ru)
CY (1) CY1118734T1 (ru)
DK (1) DK2486048T4 (ru)
EA (2) EA028491B1 (ru)
ES (1) ES2613269T5 (ru)
HR (1) HRP20170269T4 (ru)
HU (1) HUE031867T2 (ru)
IL (1) IL219124A (ru)
LT (1) LT2486048T (ru)
MX (1) MX2012003654A (ru)
PL (1) PL2486048T5 (ru)
PT (1) PT2486048T (ru)
RS (1) RS55727B2 (ru)
SI (2) SI2486048T1 (ru)
SM (2) SMT201700116T1 (ru)
TW (1) TW201118176A (ru)
WO (1) WO2011044180A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
SG10201510384UA (en) 2006-09-13 2016-01-28 Abbvie Inc Cell culture improvements
RU2520838C2 (ru) 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
WO2010048192A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9556258B2 (en) 2011-07-08 2017-01-31 Merck Sharp & Dohme Corp. Purification of fusion proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
KR102136698B1 (ko) 2012-05-02 2020-07-22 라이프 테크놀로지스 코포레이션 고밀도 성장 및 형질감염 배지 및 발현 인핸서의 독특한 페어링을 사용하는 포유동물 세포들 내의 고수율의 일시적 발현
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
RS59577B1 (sr) * 2012-06-29 2019-12-31 Bristol Myers Squibb Co Metode za smanjenje agregacije glikoproteina
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
EP2943563A1 (en) * 2013-01-10 2015-11-18 Biogen MA Inc. Medium supplements for improved process performance
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP3391942A1 (en) 2013-03-26 2018-10-24 Coherus Biosciences, Inc. Protein production method
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3683316A1 (en) * 2014-01-30 2020-07-22 Coherus Biosciences, Inc. Perfusion media
EP3122869B2 (en) 2014-03-24 2022-08-10 Biogen MA Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US10544408B2 (en) * 2014-10-21 2020-01-28 Gennova Biopharmaceuticals Limited Purification process for isolation and commercial production of recombinant TNK-tPA tenecteplase
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
CN106318998B (zh) * 2015-07-08 2019-08-20 浙江海正博锐生物制药有限公司 用于提高重组人ⅱ型肿瘤坏死因子受体-抗体融合蛋白唾液酸化水平的组合物
WO2017011598A1 (en) * 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
JP2018536404A (ja) * 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
US11753458B2 (en) 2017-10-10 2023-09-12 Alpine Immune Sciences, Inc. CTLA-4 variant immunomodulatory proteins and uses thereof
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN108659095A (zh) * 2018-05-18 2018-10-16 上海药明生物技术有限公司 一种使唾液酸含量稳定的方法
CN114592005B (zh) * 2022-04-12 2023-12-19 厦门大学 一种糖皮质激素的检测方法
JP2025538819A (ja) * 2022-12-12 2025-11-28 ジェネンテック， インコーポレイテッド ポリペプチドシアル酸含有量の最適化
CN116003633A (zh) * 2022-12-15 2023-04-25 景泽生物医药(合肥)股份有限公司 一种重组人抗vegf抗体融合蛋白的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
AU580145B2 (en) * 1985-02-13 1989-01-05 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5264550A (en) * 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0606217B2 (en) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
JPH08308561A (ja) * 1995-05-16 1996-11-26 Sumitomo Electric Ind Ltd 動物細胞培養用無血清培地
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
AU1003001A (en) 1997-01-31 2001-04-12 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
EP1092037B1 (en) 1998-05-29 2005-12-28 Genentech, Inc. Cell culture process for producing glycoproteins
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
JP4443714B2 (ja) 2000-03-28 2010-03-31 明治乳業株式会社 細胞培養におけるｂ型肝炎ウイルス表面抗原の高収率生産方法
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
TWI319405B (en) * 2000-05-26 2010-01-11 Bristol Myers Squibb Co Soluble ctla4 mutant molecules and uses thereof
AU2003303394B2 (en) 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
BR0317723A (pt) 2002-12-23 2005-11-22 Bristol Myers Squibb Co Processo de cultura de células de mamìfero para a produção de proteìna
EP1969007B1 (en) 2005-12-20 2013-08-28 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8678606B2 (en) 2010-06-14 2014-03-25 Aja Berger Carrying container with at least two light sources

Also Published As

Publication number Publication date
SI2486048T2 (sl) 2020-04-30
CN102753572A (zh) 2012-10-24
US20110081679A1 (en) 2011-04-07
CA2777050C (en) 2016-12-20
PL2486048T5 (pl) 2020-07-13
DK2486048T3 (en) 2017-02-27
AR078544A1 (es) 2011-11-16
DK2486048T4 (da) 2020-03-30
LT2486048T (lt) 2017-02-10
IL219124A (en) 2017-10-31
HUE031867T2 (en) 2017-09-28
US20170129936A1 (en) 2017-05-11
IL219124A0 (en) 2012-06-28
US10030064B2 (en) 2018-07-24
AU2010303590B2 (en) 2016-07-07
US10059754B2 (en) 2018-08-28
AU2010303590A1 (en) 2012-05-03
JP2013506436A (ja) 2013-02-28
RS55727B1 (sr) 2017-07-31
EP2486048B1 (en) 2016-11-23
EP2486048A1 (en) 2012-08-15
HRP20170269T4 (hr) 2020-04-03
PL2486048T3 (pl) 2017-07-31
MX2012003654A (es) 2012-04-30
HRP20170269T1 (hr) 2017-04-07
ES2613269T3 (es) 2017-05-23
EP2486048B2 (en) 2019-12-25
CY1118734T1 (el) 2017-07-12
CO6531436A2 (es) 2012-09-28
US20170129937A1 (en) 2017-05-11
PT2486048T (pt) 2017-02-06
TW201118176A (en) 2011-06-01
BR112012007854A2 (pt) 2016-11-22
EA025604B1 (ru) 2017-01-30
SMT201700116T1 (it) 2017-03-08
US9540426B2 (en) 2017-01-10
EA028491B1 (ru) 2017-11-30
EA201270469A1 (ru) 2012-10-30
SI2486048T1 (sl) 2017-02-28
WO2011044180A1 (en) 2011-04-14
KR20120100973A (ko) 2012-09-12
RS55727B2 (sr) 2020-09-30
ES2613269T5 (es) 2020-08-03
SMT201700116B (it) 2017-03-08
CA2777050A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
EA201270469A1 (ru) Способы культивирования клеток млекопитающих для получения белка
WO2011091350A3 (en) Methods & compositions for improving protein production
TW200512297A (en) Mammalian cell culture processes for protein production
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
BR112022013569A2 (pt) Construções de célula viva para produção de produto lácteo cultivado e métodos usando as mesmas
EA200501774A1 (ru) Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
EP4148121A3 (en) Cell-controlled perfusion in continuous culture
ATE488600T1 (de) Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
BR112012027430A2 (pt) processo de cultivo de células aprimorado
EP2438161A4 (en) PROCESS FOR THE PRODUCTION OF PLURIPOTENT STEM CELLS AND THEIR CULTURE PROCESS
MY156588A (en) Systems using cell culture for production of isoprene
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
MY169935A (en) "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
MX355650B (es) Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
EA201270213A1 (ru) Способ получения полипептида или вируса, представляющих интерес, в непрерывной клеточной культуре
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
BR112014032560A2 (pt) células para produzir iduronato-2-sulfatase recombinante
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
AR086200A1 (es) Hongos filamentosos que tienen un fenotipo de viscosidad alterado
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
FI3818078T3 (fi) Menetelmiä rekombinanttiproteiinien tuottamiseksi
EA201301163A1 (ru) Высокоэффективный способ ферментации
Liu et al. Scale high-cell-density fermentation of Pichia pastoris
EA200900984A1 (ru) Улучшение клеточного роста

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM